Researchers have identified the molecular and cellular mechanisms that transform healthy stem cells into oral cancer at the earliest stages of the disease.
NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical company valued at $58.63 million, has published results from a preclinical study on its second cancer vaccine candidate, IO112, which ...